FDA clears AbbVie’s Decnupaz for ultra-rare blood cancer
CURRENT BRIEF VERSION: AbbVie said on May 27 that the US FDA approved Decnupaz (pivekimab sunirine-pvzy) for adults with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, an ultra-rare and aggressive blood cancer. The approval covers a CD123-directed antibody-drug conjugate and is based on the single-arm Phase 1/2 CADENZA study, which enrolled 84 patients with CD123-positive hematologic malignancies, including 33 treatment-naive BPDCN patients and 51 with relapsed or refractory disease, all without active CNS disease. In the FDA’s review, 69.7% of treatment-naive patients achieved complete remission or clinical complete remission, compared with 15.7% in the relapsed or refractory group. Median duration of remission was 9.7 months in the frontline group and 9.2 months in relapsed or refractory patients, and some patients in both groups went on to stem cell transplant. The label also carries a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease. (fda.gov)
Why it matters: While this is a human oncology approval, it’s still relevant to veterinary professionals tracking the broader oncology pipeline, especially around antibody-drug conjugates and CD123-targeted approaches. BPDCN has had few approved options, with tagraxofusp becoming the first FDA-approved therapy in 2018, so Decnupaz adds a new mechanism in a very small, high-need setting. The transplant bridge signal also stands out: in reporting on CADENZA, 13 newly diagnosed patients and 6 relapsed or refractory patients were able to proceed to stem cell transplant after treatment. For clinicians and industry watchers, the approval highlights the tradeoff that often comes with highly targeted oncology drugs: meaningful activity in a hard-to-treat cancer, paired with clinically important safety monitoring requirements. (pubmed.ncbi.nlm.nih.gov)
What to watch: Next will be real-world uptake, safety experience around liver toxicity, and whether AbbVie can expand pivekimab sunirine into other CD123-positive hematologic malignancies such as acute myeloid leukemia. (biospace.com)